Table 3.

Comparison of indication, mechanism of action, route of administration and treatment schedule of the four investigated agents.

	Indication	Mechanism of action	Route of administration	Treatment schedule	Tailored vs. predefined dose
Omalizumab	For patients 6 years of age and older with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids	anti-IgE	Subcutenous	Biweekly	Tailored
Mepolizumab	For ≥12 years patients add on maintance treatment for patients with severe asthma with eosinophila (>150/μL)	anti-IL5	Subcutenous	Monthly	Predefined
Benralizumab	For ≥12 years patients add on maintance treatment for patients with severe asthma with eosinophila (>150/μL)	anti-IL5Rα	Subcutenous	Monthly for 3 months then bimonthly	Predefined
Reslizumab	For ≥18 years patients add on maintance treatment for patients with severe asthma with eosinophila (>400/μL)	anti-IL5	Intravenous	Monthly	Tailored
Remark from the survey			36.5% considered intravenous and subcutaneous route equally effective, while 23.5% preferred subcutaneous and 9.8% intravenous, 30% did not have an opinion on the topic	66% preferred monthly administration, 7% bi-weekly; 27% bi-monthly administration. 72% believed that patients prefer monthly, and 22% a bimonthly regime	54% preferred a tailored dose, 21% a predefined dose, and 11% considered these two approaches equal while 14% had not formed an opinion